Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players

Glioblastoma (GBM) represents the most frequent glial tumor, with almost 3 new cases per 100,000 people per year. Despite treatment, the prognosis for GBM patients remains extremely poor, with a median survival of 14.6 months, and a 5-year survival less than 5%. It is generally believed that GBM cre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardo, Salvo Danilo, Bramanti, Alessia, Ciurleo, Rosella, Basile, Maria Sofia, Pennisi, Manuela, Bella, Rita, Mangano, Katia, Bramanti, Placido, Nicoletti, Ferdinando, Fagone, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583708/
https://www.ncbi.nlm.nih.gov/pubmed/33123243
http://dx.doi.org/10.3892/ol.2020.12195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583708/
https://www.ncbi.nlm.nih.gov/pubmed/33123243
http://dx.doi.org/10.3892/ol.2020.12195

Ejemplares similares